Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients

Abstract

Five prospective clinical studies in lupus patients have shown that LJP 394 can reduce circulating anti-dsDNA antibody levels without causing generalized immunosuppression. The compound is currently being evaluated in a phase III clinical trial for the prevention of renal flares in patients with high-affinity antibodies to LJP 394 and a history of lupus nephritis. The current study analyzed the affinity of patient IgG for LJP 394 prior to and following 4 months of treatment with LJP 394 to determine if pretreatment affinity influenced pharmacodynamic response. Patient serum samples from a multicenter, double-blind, placebo-controlled trial were evaluated prior to and following 4 months of weekly, biweekly or monthly treatment with placebo (n=9) or weekly treatment with 10 mg LJP 394 (n=6) or 50 mg LJP 394 (n=4). After treatment there was a dose-dependent reduction in affinity in the 10 mg/week and 50 mg/week groups (P < 0.05 and P < 0.01, respectively), whereas the placebo group was unchanged. This study demonstrates that weekly treatment with LJP 394 produces a dose-dependent reduction in titer-weighted average affinity. These results suggest it may be possible to use an affinity assay to define prospectively patients that are most likely to exhibit the desired pharmacodynamic response to LJP 394.

Keywords

lupus nephritis LJP 394 affinity

Get full access to this article

View all access options for this article.

References

Isenberg DA , Ravirajan CT , Rahman A , Kalsi J . The role of antibodies to DNA in systemic lupus erythematosus <Eth> a review and introduction to an international workshop on DNA antibodies held in London May 1996 . Lupus. 1997; 6: 290–304 .

Hahn BH . Antibodies to DNA . New Engl J Med. 1998; 338: 1359–1368 .

Swaak AJ , Aarden LA , Statius van Eps LW , Feltkamp TE . AntidsDNA and complement profiles as prognostic guides in systemic lupus erythematosus . Arthrit Rheum. 1979; 22: 226–233 .

Okamura M , Kanayama Y , Amastu K et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology . Ann Rheum Dis. 1993; 52: 14–20 .

Ter Borg EJ , Horst G , Hummel EJ , Limburg PC , Kallenberg CG . Measurement of increases in anti-double-stranded DNA antibody levels as predictor of disease exacerbation in system lupus erythematosus. A long-term prospective study . Arthrit Rheum. 1990; 33: 634–643 .

Ter Borg EJ , Horst G , Hummel E , Limburg PC , Kallenberg CG . Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation . Clin Immunol Immunopathol. 1991; 59: 117–128 .

Winfield JB , Faiferman I , Koffler D . Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity anti-native DNA antibody with glomerulonephritis . J Clin Invest. 1977; 59: 90–96 .

Raz E , Brezis M , Rosenmann E , Eilat D . Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney . J Immunol. 1989; 142: 3076–3082 .

Pankewycz OG , Migliorini P , Madaio MP . Polyreactive autoantibodies are nephritogenic in murine lupus nephritis . J Immunol. 1987; 139: 3287–3294 .

10.

Ehrenstein MR , Katz DR , Griffith MH et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice . Kidney Int. 1995; 48: 705–711 .

11.

Jones DS , Barstad PA , Field MJ et al. Immunospecific reduction of anti-oligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis . J Med Chem. 1995; 38: 2138–2144 .

12.

Coutts SM , Plunkett ML , Iverson GM , Barstad PA , Berner CM . Pharmacological intervention in antibody mediated disease . Lupus. 1996; 5: 158–159 .

13.

Furie RA , Cash JM , Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394 . J Rheumat. 2001; 28: 257–265 .

14.

Sem DS , McNeeley PA , Linnik MD . Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies . Arch Biochem Biophys. 1999; 372: 62–68 .

15.

Feltkamp TE , Kirkwood TB , Maini RN , Aarden LA . The first international standard for antibodies to double stranded DNA . Ann Rheum Dis. 1988; 47: 740–746 .

16.

Blank M , Shoenfeld Y , Cabilly B et al. Prevention of experimental antiphospholipid syndrome and endothelial activation by synthetic peptides . Proc Natl Acad Sci USA 1999; 96: 5164–5168 .

17.

Stollar BD . Molecular analysis of anti-DNA antibodies . FASEB J 1994; 8: 337–342 .

18.

Kalsi JK , Martin AC , Hirabayashi Y et al. Functional and modeling studies of the binding of human monoclonal anti-DNA antibodies to DNA . Mol Immunol. 1996; 33: 471–483 .